Vetter is a global leading contract development and manufacturing organization (CDMO), headquartered in Ravensburg, Germany, with production facilities in Germany, Austria and the United States. The company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com. | Vetter is a global leading contract development and manufacturing organization (CDMO), headquartered in Ravensburg, Germany, with production facilities in Germany, Austria and the United States. The company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and compliance. Great importance is also given to social responsibility including environmental protection and sustainability. | Vetter is a leading Contract Development and Manufacturing Organization (CDMO) with headquarters in Ravensburg, Germany, and production facilities in Germany, Austria, and the US. As a global player, the independent pharmaceutical service provider is also present in the Asia-Pacific markets of Japan, China, South Korea and Singapore with sales locations. Around the world renowned pharma and biotech companies benefit from decades of experience, high quality, modern technologies, reliability, and commitment of its 7,300 employees. In close collaboration with its customers, the Vetter team helps enable the supply to patients all over the world with medicines, many of which are vital. The CDMO provides support from drug product development through clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes, and cartridges. With innovative approaches, Vetter develops prefilled drug-delivery systems together with its customers to continuously improve patient safety, comfort, and compliance. Vetter takes responsibility for sustainable practices and operates as a socially and ethically responsible corporate citizen. The CDMO is a member of the UN Global Compact and Science Based Target initiative (SBTi) and received platinum status in the renowned EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, Frost & Sullivan Customer Value Leadership Award and the recognition of Best Managed Company emphasize Vetter’s commitment to sustainable business. Founded in Ravensburg in 1950, the company remains family-owned to this day. For more information, visit www.vetter-pharma.com and follow Vetter on LinkedIn.
Vettiva Saúde Animal
Vettiva Animal Health is a biotech startup focused exclusively on Research and Development (R&D) and commercialization of innovative pharmaceuticals derived from Medical Cannabis. It is also the first company to formalizeclinical development of cannabidiol-based veterinary candidate therapies with the Brazilian Ministry of Agriculture, Livestock, and Supply (MAPA).
Veeda Lifesciences
For nearly two decades, Veeda Lifesciences has been a trusted partner in drug development, supporting pharmaceutical, biotech, and specialty healthcare companies in bringing innovative therapies to patients worldwide. Our global presence spans across 9 countries and 26 geographies, allowing us to offer localized expertise while maintaining a broad international reach. By combining scientific excellence, regulatory expertise, and cutting-edge technology, we ensure the execution of efficient, high-quality clinical trials that accelerate the drug development process. A Strategic Partner in Drug Development Veeda Lifesciences partners with innovator companies to navigate the intricate landscape of clinical research and drug development. Our comprehensive suite of services covers: Strategic Consulting: We provide expert guidance in trial design, regulatory pathways, and market access strategies, ensuring seamless progression from preclinical to clinical phases. Regulatory Support: Our regulatory affairs team assists with dossier preparation, regulatory submissions, and interactions with health authorities, streamlining the approval process. Operational Excellence: We offer end-to-end trial management solutions, including site selection, patient recruitment, monitoring, data management, and biostatistical analysis. Expertise Across Multiple Therapeutic Areas With deep domain expertise in key therapeutic areas, Veeda has played a pivotal role in advancing clinical research in: Oncology & Hematology: Our contributions include supporting one of the largest global multiple myeloma trials across 24 countries. By leveraging AI-driven patient recruitment strategies and real-world data, we optimize site selection and accelerate trial timelines. Dermatology: We have successfully executed clinical trials for novel dermatological therapies, addressing conditions such as psoriasis, atopic dermatitis, and skin cancers. Endocrinology & Metabolic Disorders: Veeda has been instrumental in conducting trials for diabetes, obesity, and other endocrine disorders, ensuring the safety and efficacy of new treatment modalities. Other Specialties: Our expertise extends to cardiovascular diseases, infectious diseases, autoimmune disorders, and rare diseases, enabling comprehensive clinical research solutions across various indications. Comprehensive Clinical Development Lifecycle Support Veeda Lifesciences offers integrated solutions across the entire clinical development lifecycle, ensuring scientific rigor, regulatory compliance, and operational efficiency at every stage: Early-Phase Studies: First-in-Human (FIH) and Phase I trials Bioavailability & bioequivalence (BA/BE) studies Pharmacokinetics (PK) and pharmacodynamics (PD) evaluations Adaptive trial designs to optimize early-stage decision-making Late-Stage Clinical Trials: Phase II-IV multi-regional clinical trials (MRCTs) Patient-centric study designs incorporating decentralized trial models Site feasibility assessments and accelerated patient enrollment strategies Global regulatory submissions and post-marketing surveillance Advanced Capabilities and Technology-Driven Approach Our commitment to technological innovation enhances trial efficiency and data integrity through: Bioanalytical Research & Central Lab Services: High-quality analytical testing for small molecules, biologics, and biosimilars, ensuring accurate pharmacokinetic and immunogenicity assessments. Digital Trial Management: AI-powered platforms for real-time data capture, electronic trial management, and remote monitoring, optimizing trial workflows. Patient Engagement Solutions: Digital tools to enhance patient retention, adherence, and real-world evidence generation, improving trial outcomes. Pharmacovigilance & Safety Monitoring: Comprehensive adverse event reporting and risk mitigation strategies, ensuring regulatory compliance and patient safety. Biopharmaceutical Development Expertise Veeda Lifesciences offers a comprehensive suite of services tailored to support the development of biopharmaceuticals, including biologics and biosimilars. Our expertise encompasses non-clinical testing solutions designed to ensure safety, efficacy, and regulatory compliance for complex biological therapies. Key Biopharma Services: Preclinical Research: We conduct rigorous preclinical studies to assess the safety and biological activity of biotherapeutic candidates, providing a solid foundation for clinical development. Bioanalytical Support: Our bioanalytical services include method development, validation, and high-throughput sample analysis, delivering precise data essential for regulatory submissions. Regulatory Consulting: We offer strategic guidance on regulatory pathways for biologics and biosimilars, assisting with dossier preparation and interactions with health authorities to streamline approvals. By integrating these services, Veeda Lifesciences ensures a seamless transition from discovery to market for biopharmaceutical products, upholding the highest standards of scientific integrity and patient safety. Beyond Clinical Trials: Integrated Research Solutions Veeda Lifesciences offers a holistic approach to drug development with a diverse range of research services, including: Preclinical Testing: In vitro and in vivo studies to assess drug safety, efficacy, and toxicity before clinical trials. Regulatory Consulting: Expert navigation of global regulatory landscapes, including US FDA, EMA, MHRA, DCGI, and other health authorities. Medical Writing & Scientific Documentation: Preparation of clinical study reports, investigator brochures, regulatory dossiers, and scientific publications to support regulatory approvals. A Trusted Partner for Advancing Life-Changing Therapies Veeda Lifesciences is committed to upholding the highest standards of scientific integrity, patient-centric research, and global regulatory excellence. Our collaborative approach, coupled with a strong emphasis on quality, innovation, and operational efficiency, makes us the preferred partner for companies seeking to bring transformative therapies to market. For more information, visit: Veeda Lifesciences
Valpharma International S.p.A.
Valpharma Group SpA is an European pharmaceutical company leader in pharmaceutical development and contract manufacturing of oral FDF solid dosage medicines and nutraceuticals, with more than 45 years expertise in commercial supply in more than 70 markets. Our plants are authorized to manufacture (IMP and commercial) powders, granulates, film-coated- not film-coated tablets (FDF), pellets bulk or capsules (FDF). Dossiers: Melatonine ER Apixaban IR Gliclazide SR Diltiazem SR In development Semaglutide IR Upadacitinib ER Mirabegron ER
VaLogic Bio
VaLogic Bio offers specialized advisory and compliance services designed to simplify complexity and promote innovation for life science and biotech companies. Our expertise spans consulting, software as a service (SaaS), laboratory services, and certification. We provide strategic guidance, advanced software solutions, precise laboratory support, and certification assistance to help organizations reach new heights, navigate regulatory challenges, and achieve operational excellence.
UNITHER PHARMACEUTICALS
Unither Pharmaceuticals is a pharmaceutical subcontractor specializing in the development and manufacturing of unit-dose and multidose liquid formulations (including eye drops, saline solutions, asthma medications in BFS unit doses, and oral liquid stick-packs) for originator pharmaceutical companies and generic manufacturers. With 2,300 employees and eight manufacturing plants across France, the United States, Brazil and China, as well as an R&D center in France, Unither Pharmaceuticals reported sales of EUR 522 million in 2024. www.unither-pharma.com
UNESP
Sao Paulo State University and V-BioPharma, a brazilian CDMO
UK Pavilion
The (UK’s) Department for Business and Trade (DBT) helps businesses export, drives inward and outward investment, negotiates market access and trade deals, and champions free trade. We are an international economic department, responsible for: • supporting and encouraging UK businesses to drive sustainable international growth • ensuring the UK remains a leading destination for international investment • opening markets, moulding the trade environment with new and existing partners which is free and fair • using trade and investment to underpin the government’s agenda for a Global Britain and its ambitions for prosperity, stability and security worldwide. | The UK’s Department for Business and Trade supports international investment into the UK and UK businesses to grow and export. Whether you’re interested in clinical research for innovative products, working with the UK’s world-leading universities, SMEs and spin outs, leveraging our globally-unique datasets or manufacturing complex products at pace and scale, the UK has a strong offer spanning Northern Ireland, Scotland and Wales and would like to work with you. We are joined by 16 inspired, innovative and international UK co-exhibitors eager to connect with you. | The UK’s Department for Business and Trade supports international investment into the UK and UK businesses to grow and export. Whether you’re interested in clinical research for innovative products, working with the UK’s world-leading universities, SMEs and spin outs, leveraging our globally-unique datasets or manufacturing complex products at pace and scale, the UK has a strong offer spanning Northern Ireland, Scotland, Wales and England and would like to work with you. This year, we are joined by 22 UK co-exhibitors eager to connect with you. | The Advanced Propulsion Centre (APC) is the organisation that pulls together exhibitors on the UK Pavilion who have advanced new technology and are looking for partner organisations to sell to or develop this technology with. The APC exists to ensure the UK remains competitive in the research, development and production of low emission technologies. Through our team of specialists we introduce those with good ideas to those who can take them to market, supporting through mentoring and providing access to funding. We are delivering a 10 year programme, launched in 2013. Born out of the collaboration between UK Government and industry, our organisation aims to save 50 million tonnes of CO2, safeguard or create 30,000 jobs in the UK and make £1 billion of match funding available to research and develop low emission propulsion technologies in the UK. | The Advanced Propulsion Centre UK (APC) collaborates with UK government, the automotive industry, and academia to facilitate driving research and investment in zero-emission vehicle manufacturing. Established in 2013 and jointly funded by the Department for Business and Trade (DBT) and the automotive industry, the APC accelerates the technologies that support the transition to zero-emission vehicle manufacturing and towards a net-zero automotive supply chain in the UK. With a proven track record, the APC has facilitated funding for 354 low-carbon and zero-emission projects involving 614 partners. Working with companies of all sizes, this funding since 2013 is estimated to have helped create or safeguard over 59,000 jobs in the UK. The technologies and products are projected to save over 425 million tonnes of CO2. The APC is committed to sustaining and enhancing the UK’s long-term automotive capabilities and investments through knowledge-sharing, collaboration, and innovation.
UI Pharmaceuticals
Contract pharmaceutical services include: Pre-formulation studies Formulation development (including lyophilization cycle development) Clinical supply manufacturing and testing Small scale commercial manufacturing and testing Analytical method development and validation Routine quality control analysis Stability studies Active pharmaceutical ingredient (API) and excipient release testing UI Pharmaceuticals is able to manufacture most dosage forms including sterile solutions and lyophilized powders; tablets; capsules; and non-sterile semisolids and liquids. | UI Pharmaceuticals stands as the longest-running, FDA-registered, university-affiliated pharmaceutical manufacturing facility in the United States. Since 1974, we have been a reliable partner in pharmaceutical product development, manufacturing, and testing, with services covering sterile solutions, lyophilized products, tablets, capsules, and non-sterile formats, including powders, semisolids, and liquids. Our experienced team brings deep industry knowledge and a commitment to the highest standards of quality, ensuring full compliance with cGMP regulations. With a steadfast dedication to client satisfaction, UI Pharmaceuticals supports innovation and excellence in contract pharmaceutical manufacturing and testing.
TJOAPACK
Tjoapack is a leading global pharmaceutical contract packaging solutions provider that operates production facilities in Europe and the US. Our extensive services cover primary packaging for oral solids, such as blister packs and bottles, as well as secondary packaging in all formats. We also specialise in custom packaging solutions for vials and pre-filled syringes. Furthermore, our services include customised kit assembly, serialisation and aggregation, product market release, clinical trial packaging, packaging for narcotic substances, re-packaging, and logistics management, along with analytical testing.